Jump Financial LLC Sells 59,951 Shares of Zoetis Inc. $ZTS

Jump Financial LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 45.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,649 shares of the company’s stock after selling 59,951 shares during the quarter. Jump Financial LLC’s holdings in Zoetis were worth $11,174,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Zoetis by 0.8% during the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock valued at $6,532,276,000 after acquiring an additional 330,823 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares during the period. Polen Capital Management LLC increased its holdings in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp increased its stake in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after buying an additional 78,508 shares during the period. Finally, Norges Bank purchased a new position in Zoetis during the 2nd quarter valued at $809,491,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 1.4%

Shares of ZTS opened at $118.69 on Monday. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $181.85. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The business’s 50 day simple moving average is $133.77 and its 200-day simple moving average is $147.57. The stock has a market capitalization of $52.31 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 2.46 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter in the previous year, the business earned $1.58 EPS. The company’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st were paid a dividend of $0.50 per share. The ex-dividend date was Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Argus reiterated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. KeyCorp began coverage on Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating for the company. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Wednesday, December 3rd. Finally, Morgan Stanley reduced their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, November 10th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.